Skip to main navigation Skip to search Skip to main content

Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial

  • Sabine Kahl
  • , Sofiya Gancheva
  • , Klaus Straßburger
  • , Christian Herder
  • , Jürgen Machann
  • , Hisayuki Katsuyama
  • , Stefan Kabisch
  • , Elena Henkel
  • , Stefan Kopf
  • , Merit Lagerpusch
  • , Konstantinos Kantartzis
  • , Yuliya Kupriyanova
  • , Daniel Markgraf
  • , Theresa Van Gemert
  • , Birgit Knebel
  • , Martin F. Wolkersdorfer
  • , Oliver Kuss
  • , Jong Hee Hwang
  • , Stefan R. Bornstein
  • , Christian Kasperk
    • Norbert Stefan, Andreas Pfeiffer, Andreas L. Birkenfeld, Michael Roden*
*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

303 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science